Revisión

Therapeutic strategy in severe encephalopathies

J. Campos-Castelló [REV NEUROL 2001;32:860-866] PMID: 11424039 DOI: https://doi.org/10.33588/rn.3209.2000530

OPEN ACCESS

Volumen 32 | Number 09 | Nº of views of the article 5.366 | Nº of PDF downloads 1.108 | Article publication date 16/05/2001

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

INTRODUCTION The severe epileptic syndromes of infancy are dependent on age, symptomatic or cryptogenic aetiology and are drug-resistant so that overall prognosis –control of epilepsy and adequate cognition– is poor so that some authors consider it to be catastrophic. All may be identified and differentiated on electroclinical criteria. DEVELOPMENT.We study the neonatal myoclonic encephalopathies in the two clinical forms described by Aicardi and Ohtahara, West’s syndrome (infantile spasms), severe myoclonic epilepsy of Dravet-Dalla Bernardina and the Lennox-Gastaut syndrome, briefly describing their electroclinical semiology and therapeutic strategies using the range of available drugs, together with other medical and surgical therapeutic options.

CONCLUSIONS Treatment of severe epileptic encephalopathies of childhood is useless/not viable in neonatal myoclonic encephalopathies and severe myoclonic epilepsy of childhood, whilst in the West and Lennox-Gastaut syndromes the results depend on the aetiology, and are better in the cryptogenic types with control of 20% and 30% of the cases but with normal intelligence in only 5% and 9%. KeywordsLennox-Gastaut syndrome Neonatal myoclonic syndromes (Aicardi and Ohtahara)Severe epileptic encephalopathies of infancy Severe myoclonic epilepsy of infancy (Dravet-Dalla Bernardina)Therapeutic strategy West’s syndrome (infantile spasms) CategoriesEpilepsias y síndromes epilépticos

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Revisión

Therapeutic strategy in severe encephalopathies